Frendy Wihono, Ginanda Putra Siregar, Syah Mirsya Warli


INTRODUCTION:Urological cancers are one of the most common type of cancers worldwide. We would
like to describe the prole of urological cancer in Indonesia.
MATERIALS AND METHODS:Data collected retrospectively from in 2013 – 2017 in Haji Adam Malik General Hospital, with
prostate cancer, kidney tumor, bladder cancer, testicular tumor, penile cancer, and adrenal tumor. We classify the data based on
the year, age, gender, pathological examination, diagnosis, treatment.
RESULTS:A total of 446 urologic cancer cases included (364 males (81.6%) and 82 females (18,3%)). Prostate cancer is the
highest cancer incidence (167 cases (37,4%)), bladder cancer 133 cases (29.9%), and penile cancer 72 cases (16.1%). The lowest
incidence is adrenal cancer 1 case (0.1%), renal 43 cases (9.6%) and testicular 30 cases (6.7%).
CONCLUSION:Indonesian urologists, other healthcare providers, government and non-government organizations must
collaborate to promote health education to minimize the incidences of urologic cancer in Medan.


Urologic Cancer, Prostate Cancer, Bladder Cancer, Penile Cancer, Adrenal Cancer

Full Text:



Jeanne Held-Warmkessel, MSN, RN, AOCN, ACNS-BC. Chapter 1: Introduction to Genitourinary Cancers. Genitourinary Cancers. Site-Specific Cancer Series. Oncology Nursing Society. 2011

Josh Gottlieb, BS, Cory Higley, BS, MPH, Roman Sosnowski, MD, PhD, et al. Smoking-related Genitourinary Cancers: A Global Call to Action in Smoking Cessation. Vol 18 No. 4. 2016. Reviews in Urology

Rainy Umbas, Ferry Safriadi, Chaidir A Mochtar, et al. Urologic Cancer in Indonesia. 2015. Japanese Joural of Clinical Oncology, 2015, 45(8) 708-712.

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr

Wahidin M, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-based cancer registration in Indonesia. Asian Pacific J Cancer Prev 2012;13:1709–10.

Zulfikar Y, Umbas R, Mochtar CA, Santoso RB, Hamid AR. Renal pelvis and ureter carcinoma in Jakarta: characteristic and risk factors. Indones J Cancer 2010;4:55–60

Report of National Basic Health Research (RISKESDAS) 2007. Indonesia: The National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia; 2008. http://labdata.litbang.depkes.go.id/menu-download/menu-download laporan (25 January 2015, date last accessed).

Hideyuki Akaza. Urologic cancer in Japan: role of Japan at the Frontier of Issue in Asia. Japanese Journal of Clinical Oncology, 2016, 46(1) 23-30.

Akaza H, Hinotsu S, Cooperberg MR, et al. Sixth joint meeting of J-CaP and CaPSURE—a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol 2013;43:56–66.

Umbas R, Hardjowijoto S, Mochtar CA, et al. Guidelines on Prostate Cancer Management of the Indonesian Urological Association. Jakarta: Indonesian Urological Association, 2011. ISBN: 978-979-25-4288-2 (in Indonesian).

Monoarfa RA, Hamid AR, Mochtar AC, Umbas R. Perspective of the Indonesian urologists in prostate cancer diagnosis. Indones J Cancer 2012; 6:97–104 (in Indonesian).

Chi-Feung Hung, Cheng-Kuang Yang, and Yen-Chuan Ou. Urologic cancer in Taiwan. Japanese Journal of Clinical Oncology, 2016, 46(7) 605-609.

Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev 2015 May 9. doi: 10.1016/j.ctrv.2015.05.003. [Epub ahead of print].

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60.

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.

Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer: clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 1945;122:1031–41.

GLOBOCAN 2012 v2.0, Cancer incidence and mortality worldwide: IARC. http://globocan.iarc.fr (May 2018, date last accessed).

Akaza H. Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the “second human genome”. Cancer Sci 2012;103:969–75.

Taiwan Cancer Registry Annual Report, 2012. Department of Health and Welfare T, 2015.

Umbas R. Bladder cancer: 10 years experiences from two tertiary care hospitals in Indonesia. Indones J Surgery 2007;35:17–22.

ChenW, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015;27:2–12.

Na YQ, Ye ZQ, Sun YH, Sun G editors. Guidelines on Urology in China. 2014 ed. Beijing: People’s Medical Publishing House 2014.

Arif MI, Santoso A, Djatisoesanto W, Notosoehardjo ISE, Joewarini E, Widodo JP. Detection of transitional cell carcinoma of the bladder with NMP test and urine sitology. Indones J Urol 2007;14:1–4 (in Indonesian).

Tiera H, Umbas R. Rapid urinary bladder cancer antigen test for the detection of transitional cell carcinoma of the bladder in Indonesian population (a preliminary study). Indones J Cancer 2013;7:41–6 (in Indonesian).

Aschorijanto A, Djatisoesanto W, Soebadi DM, Hermantha C, Soemarno T,Widodo JP. Comparison on staging accuracy in bladder cancer between MRI, trans-abdominal Ultrasound, and TUR-BT in Soetomo Hospital, Surabaya. Indones J Urol 2006;13:1–4 (in Indonesian).

Umbas R, Hardjowijoto S, Mochtar CA, et al. Guidelines on Urothelial Bladder Cancer of the Indonesian Urological Association. Indonesian Urological Association, 2014. ISBN: 978-602-18283-2-8 (in Indonesian).

Supit W, Mochtar CA, Sugiono M, Umbas R. Survival of patients with transitional cell carcinoma of the urinary bladder in Indonesia: a single institution review. Asian Pac J Cancer Prev 2011;12:549–53.

ChenW, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015;27:2–12.

Li M, He Z, Gao J, Sun Y, Li C, Huang Y, et al. Analysis of clinical characteristics of renal cell carcinoma in multi-centers. Chin J Urol 2010;31:77–80; (in Chinese).

Hamiseno D, Mochtar CA, Umbas R. Current systemic therapy in metastatic renal cell carcinoma. Indones J Cancer 2011;5:105–12.

Kinouchi T, Saiki S, Maeda O, Kuroda M, Usami M, Kotake T. Treatment of advanced renal cell carcinoma with a combination of human lymphoidblastoid interferon-alpha and cimetidine. J Urol 1997;157:1604–7.

Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S. A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma; a multicenter open study. Int J Clin Oncol 2006;11:434–40.

Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317–25.

Umbas R, Hardjowijoto S, Safriadi F, et al. Guidelines on Renal Malignant Tumor of the Indonesian Urological Association. Jakarta: Indonesian Urological Association, 2012. ISBN: 978-979-25-4289-9 (in Indonesian).

Cheng Pang, Youan Guan, Hongbo Li, et al. Urologic Cancer in China. Japanese Journal of Clinical Oncology, 2016, 46(6) 497-501.

La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010;21:1323–60.

Sankaranarayanan R, Swaminathan R, Black R (1996). Global variations in cancer survival. Cancer, 78, 2461-4.

Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, et al (2015b). The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int, 3, 135-40.

Mahdavifar N, Ghoncheh M, Pakzad R, et al (2016). Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. Asian Pac J Cancer Prev, 17, 381-6.

Eslick GD. What is a rare cancer? Hematol Oncol Clin North Am. 2012 Dec;26(6): 1137–41.

Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL. The occurrence of rare cancers in U.S. adults, 1995–2004. Public Health Rep. 125(1):28–43.

Larke NL, Thomas SL, dos Santos Silva I, Weiss HA. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control. 2011;22(8): 1097–110.

Hernandez BY, Barnholtz-Sloan J, German RR, Giuliano A, Goodman MT, King JB, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer. 2008;113(November):2883–91

Favorito LA, Nardi AC, Ronalsa M, Zequi SC, Sampaio FJB, Glina S. Epidemiologic study on penile cancer in Brazil. Int Braz J Urol. 2008 Sep-Oct;34(5):587–93.

Vatanasapt V, Sriamporn S, Martin N, Sriplung H, Chindavijak K, Sontipong S, et al. Cancer incidence in Thailand, 1988–1991.Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):475–83.

Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82(9): 1585–92.

Morris BJ. The strong protective effect of circumcision against cancer of the penis. Adv Urol. 2011;2011:812368. doi: 10.1155/2011/812368. Epub 2011 May 22.

Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009; 27:141-50.


  • There are currently no refbacks.